REV-ERB is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-09-08. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Herbal infusions may be made by pouring hot or boiling water over the plant parts and letting them steep for some time. The infusion temperature and time can vary depending on the type of plant part used and its properties. For example, some plant parts are covered in oils, which may take some time to separate. Brewing with cold water will also take much longer, usually several hours. An herbal tea may be strained or not (as with mate, where a special straw called a bombilla is used for drinking). Some herbal teas are blends that include various herbs or plant parts. Herbal infusions may also be sweetened, spiced, salted, or combined with other additives, like milk or lemon juice.
=== Primer extension === Primer extension is a two step process that first involves the hybridization of a probe to the bases immediately upstream of the SNP nucleotide followed by a ‘mini-sequencing’ reaction, in which DNA polymerase extends the hybridized primer by adding a base that is complementary to the SNP nucleotide. This incorporated base is detected and determines the SNP allele. Because primer extension is based on the highly accurate DNA polymerase enzyme, the method is generally very reliable. Primer extension is able to genotype most SNPs under very similar reaction conditions making it also highly flexible. The primer extension method is used in a number of assay formats. These formats use a wide range of detection techniques that include MALDI-TOF mass spectrometry (see Sequenom) and ELISA-like methods. Generally, there are two main approaches which use the incorporation of either fluorescently labeled dideoxynucleotides (ddNTP) or fluorescently labeled deoxynucleotides (dNTP). With ddNTPs, probes hybridize to the target DNA immediately upstream of SNP nucleotide, and a single, ddNTP complementary to the SNP allele is added to the 3’ end of the probe (the missing 3'-hydroxyl in didioxynucleotide prevents further nucleotides from being added). Each ddNTP is labeled with a different fluorescent signal allowing for the detection of all four alleles in the same reaction. With dNTPs, allele-specific probes have 3’ bases which are complementary to each of the SNP alleles being interrogated.
=== Book bans === In May 2023, during a commencement speech at Morehouse College, Moore criticized efforts to ban books and restrict curriculum in schools, suggesting that politicians who sought to "silence or rewrite the history of Black and brown people are actually afraid of people understanding their power". In April 2024, Moore signed into law the Freedom to Read Act, which prohibits public and school libraries from banning books based on partisan, ideological, or religious reasons, or based an author's origin, background, or views.
Sources: en.wikipedia.org
Freeze-casting can be applied to produce aligned porous structure from diverse building blocks including ceramics, polymers, biomacromolecules, graphene and carbon nanotubes. As long as there are particles that may be rejected by a progressing freezing front, a templated structure is possible. By controlling cooling gradients and the distribution of particles during freeze casting, using various physical means, the orientation of lamellae in obtained freeze cast structures can be controlled to provide improved performance in diverse applied materials. Munch et al. showed that it is possible to control the long-range arrangement and orientation of crystals normal to the growth direction by templating the nucleation surface. This technique works by providing lower energy nucleation sites to control the initial crystal growth and arrangement. The orientation of ice crystals can also be affected by applying electromagnetic fields as was demonstrated in 2010 by Tang et al. in 2012 by Porter et al., and in 2021 by Yin et al. Using specialized setups, researchers have been able to create radially aligned freeze-casts tailored for biomedical applications and filtration or gas separation applications. Inspired by nature, scientists have also been able to use coordinating chemicals and cryopreserved to create remarkably distinctive microstructural architectures.
1961 Discovery by Leonard Hayflick of the limit of divisions for somatic cells, named the Hayflick limit. Hayflick found that normal human cells, extracted from fetus, are able to divide only about 50 times, after that they enter a senescence phase. 1969 Immunological theory of aging proposed by Roy Walford. 1974 Formation of the National Institute on Aging (NIA) – the aging of the population began to be perceived as a problem deserving state attention (and not as a problem of separate scientific societies). Since 1984, the NIA has begun to contribute in every way to the work of the National Archive of Computerized Data on Aging (NACDA). 1977 To explain aging, Thomas Kirkwood proposed the disposable soma theory. According to the theory, the organism has only a limited amount of resources that it has to allocate between different purposes (such as growth, reproduction, repair of damage). Aging occurs due to the limitation of resources that the body can afford to spend on repair. 1985 The discovery of telomerase, a ribonucleoprotein that is able to restore shortened telomeres. The discovery was made by Elizabeth Blackburn and Carol Greider. This research is based on the theoretical works of Alexey Olovnikov. The study of telomeres and telomerase required many more years and the work of many scientists around the world. For this work, in 2009, Elizabeth Blackburn, Carol Greider and Jack Szostak received the Nobel prize, in the same year Alexey Olovnikov was awarded the Demidov Prize.
=== Kevin Rawle === Kevin Rawle (Pip Torrens) is the brash, conniving editor-in-chief of The Patriot, a right-leaning tabloid owned by Lord Norton. Yasmin enlists Kevin to circulate a fictitious claim that the Labour government suppressed an internal memo voicing concerns about Tender's fraudulent practices, thereby pinning the company's failure on the government and protecting her from legal and reputational fallout. She, Kevin and Norton attempt to persuade Labour MP Jennifer Bevan to be their source, but she refuses on principle. Yasmin later has Harper pass on the claim to FinDigest editor Edward Burgess, who publishes it; The Patriot then amplifies the claim, leading to the resignation of business secretary Lisa Dearn and opening Tender to fraud investigations and a new audit.
== Personal life == McAlpine was involved in church activities. She served as President of the Manitoba Opera Guild from 1976 to 1978. She died from breast cancer in Winnipeg on 1 October 1998. Her grave is in Kilmartin Cemetery, Middlesex County, Ontario. She left a personal bequest to the University of Manitoba Department of Biochemistry and Medical Genetics to create a graduate fellowship in her name supporting students researching medical genetics.
Sources: en.wikipedia.org
== Bibliography == Audi, G.; Kondev, F. G.; Wang, M.; et al. (2017). "The NUBASE2016 evaluation of nuclear properties". Chinese Physics C. 41 (3) 030001. Bibcode:2017ChPhC..41c0001A. doi:10.1088/1674-1137/41/3/030001. Beiser, A. (2003). Concepts of modern physics (6th ed.). McGraw-Hill. ISBN 978-0-07-244848-1. OCLC 48965418. Hoffman, D. C.; Ghiorso, A.; Seaborg, G. T. (2000). The Transuranium People: The Inside Story. World Scientific. ISBN 978-1-78-326244-1. Kragh, H. (2018). From Transuranic to Superheavy Elements: A Story of Dispute and Creation. Springer. ISBN 978-3-319-75813-8. Zagrebaev, V.; Karpov, A.; Greiner, W. (2013). "Future of superheavy element research: Which nuclei could be synthesized within the next few years?". Journal of Physics: Conference Series. 420 (1) 012001. arXiv:1207.5700. Bibcode:2013JPhCS.420a2001Z. doi:10.1088/1742-6596/420/1/012001. ISSN 1742-6588. S2CID 55434734.
Insulin helps to move sugar from the blood onto other body tissues where it's used for energy. Dulaglutide medication also slows the emptying of the stomach and may decrease appetite and cause weight loss. The Food and Drug Administration (FDA) approved dulaglutide for use in the United States in September 2014. It was approved for use in the European Union in November 2014. In 2023, it was the 63rd most commonly prescribed medication in the United States, with more than 10 million prescriptions.
Bolivia's most lucrative crop and economic activity in the 1980s was coca, whose leaves were processed clandestinely into cocaine. The country was the second largest grower of coca in the world, supplying approximately fifteen percent of the US cocaine market in the late 1980s. Analysts believed that exports of coca paste and cocaine generated between US$600 million and US$1 billion annually in the 1980s (depending on prices and output). Based on these estimates, coca-related exports equaled or surpassed the country's legal exports. Coca has been grown in Bolivia for centuries. The coca plant, a tea-like shrub, was cultivated mostly by small farmers in the Chapare and Yungas regions. About 65 percent of all Bolivian coca was grown in the Chapare region of Cochabamba Department; other significant coca-growing areas consisted of the Yungas of La Paz Department and various areas Santa Cruz and Tarija departments. Bolivian farmers rushed to grow coca in the 1980s as its price climbed and the economy collapsed. Soaring unemployment also contributed to the boom. In addition, farmers turned to coca for its quick economic return, its light weight, its yield of four crops a year, and the abundance of United States dollars available in the trade, a valuable resource in a hyperinflated economy. The Bolivian government estimated that coca production had expanded from 1.63 million kilograms of leaves covering 4,100 hectares in 1977 to a minimum of 45 million kilograms over an area of at least 48,000 hectares in 1987.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.